The grief we live with during the COVID-19 pandemic is political.

"I want nothing to do with those kinds of folks who want to decriminalize psychedelics,” Rahn told Forbes."

Plus Three is joined by author and host of the Team Human podcast, Douglas Rushkoff, to discuss some of the parallel trajectories between psychedelic and digital mainstreaming. Will COVID-19 be to psychedelics as 9/11 was to surveillance capitalism? September 11th became the excuse to implement a surveillance state and surrender digital technologies to corporations. Will we see psychedelic medicines become the go-to recovery option for COVID-related mental health fallout? We also explore what a true psychedelic renaissance might look like.

Field Trip Ventures leads the charge to use “psychedelic” as a marketing buzzword for any kind of niche therapy.

Jamon A. Rahn, CEO of psychedelic pharmaceutical startup MindMed, offered a glimpse of the future of psychedelic science, including proprietary data and hints of an “LSD neutralizer.”

Contributors to the Daily Psychedelic Video platform gather on Zoom to bless the opening of the Psychedelic Video Museum: a collection of ten years’ worth of their shared visions.

'Debbie and Doug Drop Acid in the Desert' director, Scott Brown, talks mind-altering drugs, creating psychedelic visual effects, and dealing with depression.

On the one hand, psychedelics hold promise for personal healing and transformative individual change, and when psychedelics are eventually accepted by mainstream medicine, they will likely impact mental health outcomes for the better. But the broken systems highlighted by the coronavirus pandemic offer insight into why mental health has reached epidemic proportions in the first place.

Almost all clinical psychedelic drug research is being affected in some way or another by COVID-19. But, response measures vary from one organization to the next.

As the coronavirus pandemic rages on, Christian Angermayer, the world’s largest psychedelic pharmaceutical investor and founder of ATAI Life Sciences, calls to sacrifice public health for the sake of “the economy.”

In response to the coronavirus pandemic, Christian Angermayer—the world's largest psychedelic pharmaceutical investor and founder of ATAI Life Sciences—dismisses medical experts in his desperation to reboot the economy.

The coronavirus has made it clear that psychedelic medicalization will not revolutionize mental healthcare without systemic socioeconomic change.

In the midst of increasing global engagement with the fallout of the novel coronavirus, we examine some responses to the pandemic within the "psychedelic community.” Recognizing that the US has a longstanding history of privatizing profits while socializing costs, we also discuss the normalization of a "capitalist animism"—treating social phenomena like markets or financial capital as living entities—that fixates on "economic health" at the expense of public health. As this unprecedented situation continues to unfold, we explore some considerations for this sudden period of social isolation within a broader culture of social alienation.

“The Corona Virus is a necessary purge of what is no longer in resonance,” Trinity de Guzman wrote in a recent email to his followers.

A long-fought battle for access to peyote, and a dwindling population in the United States has led Native American Church members and peyote conservationists to request that peyote be left out of decriminalization efforts.

Alan Piper is a maverick historian of ideas with a penchant for unique, deep dives into rich veins of psychedelia. Piper’s 2015 monograph, Strange Drugs Make for Bedfellows: Ernst Jünger, Albert Hofmann, and the Politics of Psychedelics was foundational for the critique explored in Brian Pace’s controversial Lucy in the Sky with Nazis: Psychedelics and the Right Wing. In this interview, Pace interviews Piper about Hofmann tripping buddy and Wehrmacht Captain Jünger, LSD and ideology— clarifying concepts and dispelling myths.

As technology and psychedelics turn to mental health, we’ll likely see a future where we are treated based on our digital biomarkers, and sold mental health services based on the personal data we surrender.

Psychedelic capitalists justify their decision to go for-profit in the ballroom of America’s most recent for-profit flop.

After decades of psychedelic nonprofits paving regulatory pathways and priming wealthy investors, for-profits are moving in to reap the rewards.

The new leaders of the psychedelic medicalization industry seem to see themselves as above their own self-proposed rules.

“Play the field right and there’s money to be made even off some of the shit companies purely based on the wave.”

Many predicted an ethical storm brewing in the lead-up to the explosion of for-profit interest in psychedelic pharmaceuticals. But, were their efforts to mitigate the damage enough to make a difference?

It's not the Hokey Pokey, but psychedelic mainstreaming seems to be what it's all about. We explore some of the realities and questions of what it means to take psychedelics "mainstream.”

Can psychedelic civil disobedience really stimulate systemic reorganization?

Our statement on a recent Chacruna article by Dr. Bia Labate.